Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer

BACKGROUND: Prolonged anti-angiogenic therapy destroys tumor vasculature, whereas vascular-normalizing doses may enhance intra-tumoral drug delivery. We hypothesize that low-dose, short-course sunitinib normalizes vasculature, enhancing chemotherapy efficacy. PATIENTS AND METHODS: In phase Ib, treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Andrea L.A., Sundar, Raghav, Wang, Ting-Ting, Ng, Thian-C, Zhang, Bo, Tan, Sing-Huang, Soh, Thomas I.P., Pang, Angela S.L., Tan, Chee-Seng, Ow, Samuel G.W., Wang, Lingzhi, Mogro, Jannet, Ho, Jingshan, Jeyasekharan, Anand D., Huang, Yiqing, Thng, Choon-Hua, Chan, Ching-Wan, Hartman, Mikael, Iau, Philip, Buhari, Shaik A., Goh, Boon-Cher, Lee, Soo-Chin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325427/
https://www.ncbi.nlm.nih.gov/pubmed/27577069
http://dx.doi.org/10.18632/oncotarget.11596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325427/
https://www.ncbi.nlm.nih.gov/pubmed/27577069
http://dx.doi.org/10.18632/oncotarget.11596

Ejemplares similares